Incidence of Human Metapneumovirus Among Older Adults in 10 High-Income Countries: A Systematic Literature Review, Meta-analysis, and Modeling Study - Scorecard - MDSpire
Advertisement
Incidence of Human Metapneumovirus Among Older Adults in 10 High-Income Countries: A Systematic Literature Review, Meta-analysis, and Modeling Study
Clinical Scorecard: Prevalence of Human Metapneumovirus in Older Adults Across Ten Affluent Nations: A Comprehensive Literature Review, Meta-Analysis, and Modeling Approach
At a Glance
Category
Detail
Condition
Human metapneumovirus (hMPV) infection causing lower respiratory infections (LRI)
Key Mechanisms
Respiratory virus causing seasonal infections with partial and transient immunity leading to reinfections; associated with pneumonia and exacerbations of chronic respiratory diseases
Target Population
Older adults aged ≥60 years in high-income countries
Care Setting
Community and hospital settings including outpatient and inpatient care
Key Highlights
hMPV accounts for approximately 7.0% (95% CI, 5.4%–9.1%) of lower respiratory infection episodes in adults aged ≥60 years.
Incidence rates of hMPV-associated LRI in older adults vary by country, ranging from 185.7 to 462.1 cases per 100,000 population in 2019.
hMPV infections can cause severe disease especially in older adults, with complications including pneumonia, congestive heart failure, and exacerbations of chronic respiratory diseases.
Guideline-Based Recommendations
Diagnosis
Consider hMPV in differential diagnosis of acute respiratory infections in older adults, especially during winter to early summer seasons.
Recognize that hMPV may be underdiagnosed due to atypical presentations and exacerbations of chronic conditions masking viral infection.
Management
Current treatment is supportive; no specific antiviral therapies are available.
Monitor for complications such as pneumonia and exacerbations of chronic respiratory diseases.
Monitoring & Follow-up
Surveillance inclusion of hMPV is recommended to better estimate incidence and outcomes.
Monitor older adults with respiratory symptoms closely due to higher risk of severe disease.
Risks
Older adults (>65 years), very young children, and immunocompromised individuals are at higher risk for severe hMPV disease.
Reinfections are common due to partial and transient immunity.
Patient & Prescribing Data
Older adults aged ≥60 years in high-income countries
No specific therapies or vaccines currently available; supportive care is standard. Combination vaccines for hMPV and RSV are in clinical development.
Clinical Best Practices
Include hMPV testing in respiratory infection panels for older adults presenting with LRI symptoms.
Provide supportive care and monitor for respiratory complications in older adults with hMPV infection.
Advocate for inclusion of hMPV in routine respiratory virus surveillance programs.
Educate patients and caregivers about the potential severity of hMPV in older adults and the importance of early medical evaluation.
Machine learning analysis identifies 11 jurisdictions—including the District of Columbia, Massachusetts, and Hawaii—with the highest vulnerability to influenza-like illness.
